Abramson, Alex http://orcid.org/0000-0003-4876-9751
Caffarel-Salvador, Ester http://orcid.org/0000-0002-2844-7598
Soares, Vance
Minahan, Daniel http://orcid.org/0000-0003-3065-055X
Tian, Ryan Yu
Lu, Xiaoya
Dellal, David
Gao, Yuan
Kim, Soyoung
Wainer, Jacob
Collins, Joy
Tamang, Siddartha
Hayward, Alison
Yoshitake, Tadayuki
Lee, Hsiang-Chieh
Fujimoto, James http://orcid.org/0000-0002-0828-4357
Fels, Johannes http://orcid.org/0000-0002-6616-6746
Frederiksen, Morten Revsgaard http://orcid.org/0000-0003-0000-4426
Rahbek, Ulrik
Roxhed, Niclas
Langer, Robert http://orcid.org/0000-0003-4255-0492
Traverso, Giovanni http://orcid.org/0000-0001-7851-4077
Funding for this research was provided by:
Novo Nordisk
Department of mechanical engineering, MIT Brigham and woman's hospital division of gastroenterology
National Science Foundation
MIT undergraduate research opportunities program
Foundation for the National Institutes of Health (R01-CA075289-21, R01-CA075289-21, R01-CA075289-21, EB-00244)
Olof Viking Bjork scholarship trust
Article History
Received: 20 December 2018
Accepted: 28 August 2019
First Online: 7 October 2019
Competing interests
: A.A., E.C.-S., D.D., N.R., M.R.F., Y.G., R.L. and G.T. are co-inventors on multiple patent applications describing oral biologic drug delivery. J. Fels, M.R.F. and U.R. work for Novo Nordisk. A.A., R.L. and G.T. report having received consulting fees from Novo Nordisk. A.A. reports having received consulting fees from Eli Lilly. Complete details of all relationships for profit and not for profit for G.T. can found at ExternalRef removed. For a list of entities with which R.L. is involved (compensated or uncompensated), see ExternalRef removed.